Cysteine‐Rich Protein 61 (CCN1) Deficiency Alleviated Cardiac Remodeling in 5/6 Nephrectomized Mice by Suppressing the MAPK Signaling Pathway
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1) , 6813183
Abstract
Background: With the progression of chronic kidney disease (CKD), we can often observe cardiac remodeling, fibrosis, and cardiac failure in patients. Cysteine‐rich protein 61 (CCN1) is an extracellular matrix protein that plays a reuse role in cardiac remodeling. However, whether CCN1 participates in the crosslink between the heart and kidney in CKD and the potential mechanism remains unknown. Methods: We constructed a mouse model of CKD by 5/6 nephrectomy (5/6 Nx). Hematoxylin–eosin staining (H&E), Masson’s trichrome staining, and Sirius red staining were used to observe cardiac morphology and fibrosis. H9c2 cells were treated with si‐CCN1 or si‐NC or mitogen‐activated protein kinase (MAPK)–related inhibitors or agonist before being cultured with 5/6 Nx mouse serum. The relative protein level was detected by Western blotting. Results: We observed that CCN1 expression was markedly enhanced in the serum and heart tissues, accompanied by disordered myocardial arrangement, obvious cardiac fibrosis, hypertrophy, and decreased cardiac systolic function reflected by echocardiography. The relative markers collagen 1 (COL‐1), transforming growth factor‐ β (TGF‐ β ), heavy‐chain cardiac myosin (MyHC), and atrial natriuretic peptide (ANP) presented an increase in expression. In vivo and in vitro, after the knockdown of CCN1, the above results in the CKD group or CKD serum group were reversed; in addition, the MAPK signaling pathway was obviously activated due to 5/6 Nx, which was abolished by CCN1 inhibition. CCN1 silencing or MAPK pathway inhibition also decreased the expression of myocardial fibrosis and hypertrophy markers in H9c2 cells, while MAPK‐related agonist partly reversed the effect of CCN1 inhibition. Conclusion: Our in vivo and in vitro study showed that specific CCN1 deficiency markedly alleviated cardiac remodeling in 5/6 Nx mice through the inhibition of the MAPK pathway.Keywords
Funding Information
- Key Research and Development Program of Zhejiang Province (2019C03012)
- National Natural Science Foundation of China (82003750)
- National Natural Science Foundation of China (81671403)
- National Natural Science Foundation of China (82070446)
- Wenzhou Municipal Science and Technology Bureau (Y20210136)
- Natural Science Foundation of Zhejiang Province (LQ21H020009)
- Natural Science Foundation of Zhejiang Province (LY22H020004)
This publication has 37 references indexed in Scilit:
- CCN1/Cyr61 Stimulates Melanogenesis through Integrin α6β1, p38 MAPK, and ERK1/2 Signaling Pathways in Human Epidermal MelanocytesJournal of Investigative Dermatology, 2018
- The matricellular protein CCN1 in tissue injury repairJournal of Cell Communication and Signaling, 2018
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policyThe Lancet, 2017
- Clinical management of the uraemic syndrome in chronic kidney diseaseThe Lancet Diabetes & Endocrinology, 2016
- Extracellular Matrix Communication and Turnover in Cardiac Physiology and Pathology2015
- Molecular basis of physiological heart growth: fundamental concepts and new playersNature Reviews Molecular Cell Biology, 2012
- CCN1/CYR61: the very model of a modern matricellular proteinCellular and Molecular Life Sciences, 2011
- Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblastsJournal of Cellular Biochemistry, 2005
- The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathyProceedings of the National Academy of Sciences, 2001
- Hypoglycemia Associated with Renal FailureEndocrinology and Metabolism Clinics of North America, 1989